23 March 2016 | Press releases

Video: A partnership to revolutionize MDR-TB treatments around the world

Tuberculosis (TB) has now overtaken HIV as the deadliest infection worldwide, and we’re also losing ground to drug-resistant TB. Worse still: treatments for ‘multidrug-resistant tuberculosis’ (MDR-TB) are long, ineffective and have terrible side effects, including acute psychosis and permanent deafness.

After 50 years without new TB drugs, two were developed recently: bedaquiline and delamanid.

We’re partnering with leading medical organizations to get these drugs to patients in 15 countries, and revolutionise MDR-TB treatments. It’s called endTB.

View All News

Featured News

21 February 2024

Unitaid-backed research underpins WHO recommendation for first-ever multidrug-resistant TB prevention regimen for children

Read More

02 February 2024

Need to improve oxygen access has not ended with the pandemic

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.